BioSpace News Archive

Whole exome sequencing is expected to receive a staggering demand as DNA sequencing and its advances pave the way in the research field with the transformation of genomics.

Fact.MR has published a latest research report about the overall market dynamics of the global oligonucleotide synthesis market.

The increasing diversity of SARS-CoV-2 variants and the potential higher infectivity of some new viral strains, underline the need to identify, trace and track mutations across the complete viral genome.

Dr. Shujie Cui has developed a (N+S) Antigen test with great sensitivity and is planning to create the first Saliva N+S Antigen Test

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX)) today announced the closing of its previously announced underwritten public offering (the of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$).

Fund will provide support for minority-owned early-stage healthcare companies and is a component of Lilly’s racial justice efforts

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced the appointment of Warren Everitt to its Board of Directors (the “Board”), effective immediately.

- Average Daily Testing in January 2021 to Date Up 158% Over December 2020, Driven Primarily by Scale Up in Testing Contracts - - Company Increases Production of Assay Kits (Tests) and Sample Collection Kits to Meet Further Demand -

Cyxone announced that the first patient has been screened in the Phase 2 clinical trial of Rabeximod in Covid-19.

Salarius Pharmaceuticals, Inc. announced that Daniela Y. Santiesteban, Ph.D., Director of Research and Business Development at Salarius Pharmaceuticals, has been invited to participate in a panel discussion during Noble Capital Markets’ 17th Annual Small & Microcap Investor Conference.